Belgian drugmaker UCB has inked a $480 million deal to team up with Neuropore Therapies on some early-stage treatments for Parkinson's disease.
Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter.
Improved access by researchers to corporate clinical trial data, much like open-source software, is expected to help facilitate a conversation between academia and the business world that could both facilitate translational research and help to validate corporate research. Yale University and Johnson & Johnson have announced the first such deal to enable external investigator access to medical device and diagnostics clinical data from J&J.
Scientists in Canada say they have drilled down into the massive data files from the development effort for cholesterol drug dalcetrapib and found that a subset of patients with the right genetic profile benefited greatly from the drug. And now they plan to follow up with a new study in an effort to revive the long-dead drug.
Enanta Pharmaceuticals, perhaps best known as AbbVie's partner in hepatitis C, has blueprinted its next big solo step, joining the race to develop treatments for a pervasive liver disease with blockbuster potential.
Boston Scientific CEO Michael Mahoney described the challenge of continuing to innovate amid the shifting reimbursement sands at the JP Morgan Healthcare Conference in San Francisco.
Partners Intrexon and Ziopharm are cutting in on the fervor over a new class of immunotherapies for cancer, striking a deal with the University of Texas' MD Anderson Cancer Center.
RNAi specialist Tekmira Pharmaceuticals expanded its reach with the announcement of the purchase of OnCore Biopharma, developer of an all-oral candidate for hepatitis B, saying that a combination therapy approach is the optimal way to treat that disease.
Billionaire physician and biotech entrepreneur Patrick Soon-Shiong has launched a company devoted to immuno-oncology, licensing a treatment from Amgen to get rolling in the field.
SAN FRANCISCO-- Keeping up the rear in a three-way race to commercialize the first of a new class of anticholesterol antibodies, Pfizer is at work on a pill that attacks the same target, planning to build a franchise in what is expected to be a blockbuster new therapeutic area.